Table 1

Patient demographics and baseline characteristics

Etrolizumab SAD (n=20)Placebo SAD (n=5)Etrolizumab MD (n=18)Placebo MD (n=5)
Gender, male (%)15 (75)2 (40)13 (72)3 (60)
Age (years), mean (SD)40.3 (10.5)30.2 (11)44 (14)39 (19)
Disease duration years, median (range)8 (2–24)6 (5–29)6.5 (2–30)5.3 (2–25)
Concomitant drug treatment, n (%)
 5-ASA12 (60)4 (80)12 (67)2 (40)
 Azathioprine3 (15)1 (20)2 (11)1 (20)
 Mercaptopurine2 (10)0 (0)0 (0)0 (0)
 Methotrexate1 (5)0 (0)1 (6)0 (0)
 Corticosteroids11 (55)3 (60)8 (44)4 (80)
Previous anti-TNF therapy, n (%)  NA  NA13 (72)2 (40)
Baseline MCS, median (range)9 (5–12)9 (7–10)10 (4–12)10 (8–11)
  • 5-ASA, 5-aminosalicylic acid; MCS, Mayo Clinic Score; MD, multiple dose; NA, not applicable; SAD, single ascending dose; TNF, tumour necrosis factor.